Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2009

View Archived Issues

Inotek reports results from phase I/II clinical trial of INO-8875 in glaucoma

Boehringer Ingelheim discloses CGRP antagonists for the treatment of migraine

Abbott describes novel vitamin D receptor activators for the treatment of bone disorders

LB-03002 significantly reduces fat mass in adults with growth hormone deficiency

Phase III data on 13-valent vaccine show coverage against pneumococcal disease

Secondary leukemias seen with ibritumomab in indolent/aggressive lymphoma patients

Small study suggests donepezil can improve sleep apnea

Antisense Therapeutics completes CSR for phase IIa clinical trial of ATL/TV1102 in MS

Sorafenib beneficial in phase II differentiated thyroid carcinoma trial

Evotec completes phase I study of EVT-401 in healthy male volunteers

FEVER trial analysis shows reduced cardiovascular event risk in lower-risk patients with felodipine

Ardea Biosciences' MEK inhibitors show efficacy in arthritis model

Takeda submits additional indication and NDA applications for alogliptin

Achillion starts dosing in first-in-human ACH-1625 trial for hepatitis C

Innate reports phase IIa results for IPH-1101 in hepatitis C virus infection

CSL to commence trial of novel H1N1 swine flu candidate vaccine

Biolex completes enrollment in SELECT-2 phase IIb Locteron trial in HCV

AcelRx presents phase II results from ARX-01 Sufentanil NanoTabs trial in pain

Cephalon submits Nuvigil sNDA for sleepiness associated with jet lag disorder

Pozen submits NDA for PN-400 in collaboration with AstraZeneca

Ablynx advances ALX-0061 into preclinical development for autoimmune diseases

Novartis initiates phase III clinical study of NVA-237 in COPD

AlphaRx and Gaia report preclinical results from studies of GAI-122 for postoperative delirium

Vantia reports results from phase IIa clinical trial of VA-106483 in nocturia

Palkion initiates preclinical development of anemia drug that modulates HIF-PH

FDA granted marketing approval for AMAG's Feraheme in chronic kidney disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...